Intravenous immunoglobulin (IVIG) treatment is beneficially used in autoimmune disorders including myasthenia gravis (MG) although its mode of action and active components are still not fully identified. In an attempt to isolate from IVIG a disease-specific suppressive fraction, IVIG was passed on columns of IgG from rats with experimental autoimmune MG (EAMG) or from MG patients. These chromatographies resulted in depletion of the suppressive activity of IVIG on rat EAMG whereas the minute amounts of IgG fractions eluted from the EAMG- or MG-specific columns retained the immunosuppressive activity of IVIG. These results demonstrate that a minor disease-specific immunoglobulin fraction present in IVIG is essential for its suppressive activity.
Bibliographical noteFunding Information:
This research was supported by grants from The Muscular Dystrophy Association of America (MDA), The European Commission (EC, No QLG1-CT-2001-10918, QLRT-2001-00225 and LSHN-CT-2006-037833) and The Wood–Byer Foundation.
- Disease-specific anti-antibodies
- Experimental autoimmune myasthenia gravis (EAMG)
- IVIG (intravenous immunoglobulin) therapy
- Myasthenia gravis (MG)